More from these Authors

• Case | HBS Case Collection | 2013

  iMatari

  Joseph L. Badaracco and Matthew Preble

  In late 2012, recent Harvard Business School graduate Hannah Lopez is given the opportunity to lead entry into a new market for Plámo, a company that created startup companies in Europe and emerging markets based upon existing successful business models. She had only been with the company a few months, and while excited by the opportunity, she was beginning to have some doubts about the company. In the brief time she had been with the company, she had had a few experiences that made her question the company's approach to management and the sustainability of its business. Accepting the assignment could give her a unique entrepreneurial opportunity, but she wondered what level of support she could expect to receive and, if the startup did fail, what impact would that have on her career and reputation? Lopez was also starting to worry about the ethical implications of Plámo's style of entrepreneurship. She worried that by agreeing to serve as a manager of the new operations, she would be tacitly supporting elements of Plámo's strategy and practices that she was concerned about. Was she comfortable taking other companies' ideas and simply copying them? Was this true entrepreneurship?

  Keywords: ethical behavior; Ethical Judgment; ethics; entrepreneurship; imitation; Ethics; Moral Sensibility; Values and Beliefs; Europe; Middle East;

  Citation:

  Badaracco, Joseph L., and Matthew Preble. "iMatari." Harvard Business School Case 313-083, March 2013.

  CiteView Details

  Related

• Course Overview Note | 2013 (Revised from original 2013 version)

  The Entrepreneurial Manager: Course Overview, 2013 Winter Term

  Richard G. Hamermesh, Richard G. Hamermesh and Thomas Eisenmann

  Course overview of The Entrepreneurial Manager.

  Keywords: Entrepreneurship; Management; Business Education;

  Citation:

  Hamermesh, Richard G., and Thomas Eisenmann. "The Entrepreneurial Manager: Course Overview, 2013 Winter Term." Harvard Business School Course Overview Note 813-155, January 2013. (Revised from original January 2013 version.)

  CiteView DetailsPurchase

  Related

• Case | HBS Case Collection | 2013 (Revised from original 2012 version)

  Companion Diagnostics: Uncertainties for Approval and Reimbursement

  Richard G. Hamermesh, Norman C. Selby and Phillip Andrews

  The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questioned whether the traditional models of reimbursement were relevant in the era of personalized medicine, and who should be covering the cost of tests needed to identify the sometimes small number of patients who could benefit from expensive targeted drugs. This case focuses on the array of possibilities and the ambiguity surrounding these regulatory and reimbursement issues.

  Keywords: models of reimbursement; personalized medicine; regulation; healthcare reform; Health Care and Treatment; Health Industry; United States;

  Citation:

  Hamermesh, Richard G., Norman C. Selby, and Phillip Andrews. "Companion Diagnostics: Uncertainties for Approval and Reimbursement." Harvard Business School Case 813-037, January 2013. (Revised from original November 2012 version.)

  CiteView DetailsPurchase

  Related